Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | 28,054 | reported | 18 Aug 2025 | tx 46+202,832−133,925 |
| Dianthus Therapeutics, Inc. /DE/ | 18,188 | reported | 01 Jun 2021 | tx 7+76,411−206,454 |
| Kaleido Biosciences, Inc. | 15,000 | reported | 30 Jun 2021 | tx 9+759,193−1,285,347 |
| Global Blood Therapeutics, Inc. | 15,000 | reported | 16 Jun 2016 | tx 2+45,000 |
| Syros Pharmaceuticals, Inc. | 11,000 | reported | 11 Jun 2019 | tx 2+24,000 |
| Tekla World Healthcare Fund | 10,917 | reported | 17 Aug 2015 | tx 1+10,917 |
| BRISTOL MYERS SQUIBB CO | 9,341.7 | reported | 30 Jun 2021 | tx 31+136,923.58−8,261 |
| Sarepta Therapeutics, Inc. | 9,126 | reported | 28 Feb 2020 | tx 8+37,244 |
| Tekla Healthcare Opportunities Fund | 5,000 | reported | 28 Jul 2014 | tx 1+5,000 |
| H&Q LIFE SCIENCES INVESTORS | 2,388 | reported | 24 Jun 2014 | tx 3+2,259−2,077 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 18 Aug 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 450.00 USD | |
| 18 Aug 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 70.20 USD | |
| 18 Aug 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 0.00 USD | deriv |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 882 | 273.75 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 301 | 275.63 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 1,263 | 277.16 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 1,239 | 278.01 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 432 | 280.03 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 372 | 281.10 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 802 | 282.03 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 1,728 | 282.81 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 1,617 | 283.83 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 660 | 273.16 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 431 | 271.68 USD | |
| 15 May 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 131.21 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 729 | 268.56 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 245 | 269.79 USD | |
| 15 May 2025 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 549 | 267.14 USD | |
| 15 May 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 0.00 USD | deriv |
| 08 May 2025 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 775 | 0.00 USD | |
| 08 May 2025 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 1,558 | 0.00 USD | deriv |
| 16 May 2024 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 5,228 | 0.00 USD | deriv |
| 27 Dec 2023 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 30,000 | 195.00 USD | |
| 27 Dec 2023 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 30,000 | 96.45 USD | |
| 27 Dec 2023 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 30,000 | 0.00 USD | deriv |
2 purchases reported after at least 12 months of silence — most recent on 28 Feb 2019.